| [9] |
邱录贵，安刚.多发性骨髓瘤的现状与展望[J].中华血液学杂志，2011，32（10）：649-651.
|
| [14] |
汪娟，傅琤琤，吴德沛，等.自体造血干细胞移植治疗多发性骨髓瘤的回顾性疗效分析[J].中华医学杂志，2013，93（2）：114-118.
|
| [1] |
Blade J，Rosifiol L，Cibeira MT，et al.Hematopoietic stem cell transplantation for multiple myeloma beyond 2010[J]. Blood，2010，115（18）：3655-3663.
|
| [2] |
张之南，沈悌.血液病诊断及疗效标准[M].3版.北京：科学出版社，2007：232-235．
|
| [4] |
Kyle RA，Rajkumar SV.Multiple myeloma[J].N Engl J Med，2004，351（18）：1860-1873.
|
| [5] |
Siegel RL，Miller KD，Jemal A.Cancer statistics[J].CA Cancer J Clin，2015，65（1）：5-29.
|
| [3] |
Anderson KC，Alsina M，Bensinger W，et al.Multiple myeloma Clinical practice guidelines in oncology[J].J Natl compr Canc Netw，2011，9（10）：1146-1183.
|
| [6] |
Martinez-Lopez J，Blade J，Mateos MV，et al.Long-termprognostic significance of response in multiple myeloma after stem cell transplantion[J].Blood，2011，118（3）：529-534.
|
| [7] |
Brenner H，Gondos A，Pulte D.Recent major improvement in long-term survival of younger patients with multiple myeloma[J].Blood，2008，111（5）：2521-2526.
|
| [8] |
Pulte D，Redaniel MT，Brenner H，et al.Recent improvement in survival of patients with multiple myeloma：variation by ethnicity[J].Leuk Lymph，2014，55（5）：1083-1089.
|
| [10] |
Barlogie B，Mitchell A，van Rhee F，et al.Curing myeloma at last：defining criteria and providing the evidence[J]. Blood，2014，124（20）：3043-3051.
|
| [11] |
Hahn T，Wingard JR，Anderson KC，et al.The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma：an evidence-based review[J].Biol Blood Marrow Transplant，2003，9（1）：4-37.
|
| [12] |
Artinez-Lopez J，Blade J，Mateos MV，et al.Long-term prognostic significance of response in multiple myeloma after stem cell transplantation[J].Blood，2011，118（3）：529-534.
|
| [13] |
Cook G，Ashcroft AJ，Cairns DA，et al.The efect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma （final results from BSBMT/UKMF Myeloma X Relapse [Intensive]）：a randomised，open-label，phase 3 trial[J].Lancet Haematol，2016，3（7）：e340-e351.
|
| [15] |
Zhang Q，Bat H，Wang CB，et al．Bortezomib combined withautologousperipheral blood hematopoietic stem celltransplantation for therapy of patients with multiple myelo ma[J]．Zhongguo Shi Yan Xue Ye Xue Za Zhi，2011，19（5）：1234-1236.
|
| [16] |
Sonneveld P，Goldschmidt H，Rosinol L，et al.Bortezomibbased versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma：a meta-analysis of phaseⅢ randomized，controlled trials[J].J Clin Oncol，2013，31（26）：3279-3287.
|
| [17] |
Cornell RF，D'Souza A，Kassim AA，et al.Maintenance versus induction therapy choice on outcomes after autologous transplantation for multiple myeloma[J].Biol Blood Marrow Transplant，2017，23（2）：269-277.
|
| [18] |
Hahnast C，Von Lilienfeldtoal M，Van HP，et al.Improved progression-free survival and overall survival with thalidomide maintenance therapy in multiple myeloma：a metaanalyis of randomized trials in 2274 patients[J].Haematol Hematology J，2010，95（3）：391.
|
| [19] |
Blade J，Cibeira MT，Fernandez DC，et al.Multiple myeloma[J].Ann Oncol，2010，21 Suppl 7：S313-S319.
|
| [20] |
Schmidt-Hieber M，Blau IW，Trenschel R，et al.Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma[J]. Bone Marrow Transplant，2007，39（7）：389-396.
|
| [21] |
Barlogie B，Attal M，Crowley J，et al.Long-term follow-up of autotransplantation trials for multiple myeloma：update of protocols conducted by the Intergroupe Francophone du Myelome，Southwest Oncology Group and the University of Arkansas for Medical Sciences[J].J Clin Oncol，2010，28（7）：1209-1214.
|
| [22] |
CohenYC，ZuckermanT，YeshurunM，etal.Efficacyandsafety of autologous hematopoietic cell transplantation in elderly patients with multiple myeloma：a retrospective national multi-site cohort study[J].Ann Hematol 2017，96（2）：271-278.
|
